Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study
Gonzalez V.H., Berger B., Goldberg R., Gordon C.M., Khurana R.N., Angeles R., Shams N.
View publication
-
Therapeutic Area
Back of the eye (BOTE)
-
Categories
Clinical development
-
Affiliations
Valley Retina Institute, TX, McAllen, United States; Retina Research Center, TX, Austin, United States; Bay Area Retina Associates, CA, United States; MI, Jackson, United States; Northern California Retina Vitreous Associates, Mountain View, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA; Santen USA, Emeryville, CA, USA; ProQR Therapeutics NV, MA, Cambridge, United States